![Alex Trebeks Cbd Gummies: A Practical Look At The Celebrity Linked Trend [zydRGYwbdTp]](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-5469158-150x150.jpg "Alex Trebeks Cbd Gummies: A Practical Look At The Celebrity Linked Trend [zydRGYwbdTp] 9")
GLP-1 and Cannabis Use Disorder: The BMJ Study Explained
A BMJ cohort study of 606,434 veterans found GLP-1 drugs reduced cannabis use disorder risk by 14% and SUD-related deaths by 50%. Full clinical breakdown.
CED Cannabis Science Digest: 3 Behavior and Safety Signals Worth Watching
No fresh human clinical-trial-level cannabis paper cleared the lead threshold on June 19, 2026, but three verified cannabis behavior safety signals were still worth preserving. These signals include stigma related to cannabis use disorder, driving…
CED Cannabis Science Digest: 3 Safety Signals Worth Watching
This digest highlights prenatal cannabis safety signals verified in 2026, focusing on exposure risks, inflammatory bowel disease evidence, and semisynthetic cannabinoids. These signals provide important counseling insights without overstating treatment…
CED Cannabis Science Digest: 3 Lower-Certainty Signals Worth Watching
No fresh cannabis paper cleared CED Clinic's high-threshold lead-post bar on June 18, 2026, but three verified lower-certainty signals on insomnia, impaired driving, and legal-market pricing were still worth preserving. The cannabis insomnia trial…
CB2 Agonists and the Blood-Brain Barrier: Why This Preclinical Signal Is Still Early
A June 2026 preprint found that orally bioavailable CB2 agonists improved inflammatory and blood-brain-barrier readouts in experimental models. The signal is mechanistically interesting, but it is not human treatment evidence.
Dronabinol for Chronic Low Back Pain: What the Veterans Trial Will Actually Test
A new dronabinol chronic low back pain trial protocol focuses on safety and tolerability in Veterans. This phase IIa study will test oral dronabinol versus placebo. It is designed to inform future research, not prove efficacy.
Cannabinoids and the Aging Brain: Why Dose and Product Type Matter
A 2026 review highlights how cannabinoid therapy aging brain effects depend on dose, product type, and aging physiology. The findings emphasize careful, age-adapted decisions over broad claims. This supports safer cannabis use tailored to older adults'…
Cannabinoids and Inflammation: A Systematic Review of Clinical Evidence
Cannabinoid use inflammatory biomarkers show complex associations with both pro- and anti-inflammatory markers. Clinical evidence reveals nuanced immunomodulatory effects rather than a simple inflammatory shift. Understanding these biomarkers is critical…
Endocannabinoid System and Opioids: What a New Review Says About Pain and OUD
A 2026 review discusses the endocannabinoid system opioid use disorder connection and its potential role in pain and withdrawal management. The biology is plausible but clinical translation remains limited. This review cautions against replacing proven…
Cannabis and Cognition in Adolescents and Young Adults: A New Systematic Review
A 2026 systematic review highlights adolescent cannabis memory effects as the most consistent cognitive difference in young users. Memory-related findings, especially episodic and working memory, stand out more than other cognitive domains. This review…